BYOT.L Regulatory News (BYOT)

18 Apr 2007 07:45

Byotrol PLC18 April 2007 BYOTROL PLC UPDATE ON TRADING AND RESULTS OF INDEPENDENT TRIAL The Directors of Byotrol plc (the "Company") are pleased to be able to providean update on the recent strong progress made across the group following the endof its financial year to 31 March 2007 and to report that direct product salesrevenues will be in line with the Directors' expectations and in the lastquarter of the financial year £240,000 of sales orders were delivered. The Company has made significant progress across all of its target markets inthe year to 31 March 2007 and has been successful in attracting a number of newclients with global scale which the Directors believe will generate significantnew sales revenue to the Company. Within the UK industrial medical sector Byotrol is pleased to be able toannounce it has recently shipped an order for more than 20,000 litres of Byotrolconcentrates which will be used in a speciality medical application. The Company is also working on a number of new applications for Byotrol wherethe Directors see significant opportunities for sale of Byotrol. By way ofexample, a number of leading UK agricultural distributors have recently placedorders with the Company for disinfectant and wipe products containing Byotrol'stechnology. Similarly in the pet care niche, sales of a range of groomingproducts containing Byotrol in leading retailer Pets at Home have significantlyexceeded projections and the product range was recently recognised as newproduct of the year by Pets At Home The Company's ongoing testing and validation programme has also made strongprogress and the Directors are pleased to be able to announce the publication ofa North American study detailing the positive effects of the Company'sPolysphere(R) product in battling multidrug-resistant organisms ("MDROs"). Thisstudy has resulted in the participating hospital incorporating Byotrol productsinto its cleaning regime and this represents a very encouraging step inpenetrating the US healthcare market. The study, carried out by hospital based researchers at Monroe Hospital,Bloomington, Indiana found that Polysphere(R) provided "residual disinfectingproperties to surfaces that may become contaminated by MDROs" and that inparticular it was "effective for up to three (consecutive) days post treatment". All surfaces were inoculated using Vancomycin Resistant Enterococcus faecalis ("VRE") and Methicillin Resistant Staphylococcus Aureus ("MRSA"). The study foundthat for three consecutive days no growth of VRE occurred and that growth ofMRSA was so sparse that it "could be considered no growth". The full text of the paper can be found by following this link: http://www.monroehospital.com/UserFiles/File/A_weapon_against_superbugs_2.pdf Commenting on the recent successes Byotrol plc Chief Executive David McRobbiesaid: "These recent successes demonstrate our ability to commercialise an innovativetechnology and generate future revenue streams across our target markets. "Equally pleasing is the successful study within North America because thisvalidates our technology in another marketplace. Importantly the work at MonroeHospital demonstrates our ability to establish a trial that proves the efficacyof our technology and to convert that into product sales in the highly demandingUS healthcare market." The preliminary results for the year ended 31 March 2007 are expected to beannounced in June 2007. Enquiries: Byotrol plc 0161 277 9518 Stephen FalderDeputy Chairman Richard Bell 07825 204110Finance Director Charles Stanley Securities 020 7149 6457 Philip Davies McCann Erickson PR 01625 822540 Jim Rothnie This information is provided by RNS The company news service from the London Stock Exchange